Navigation Links
BioHealth Innovation, Inc. Appoints Qiagen's Douglas Liu to Board of Directors

ROCKVILLE, Md., April 30, 2012 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the appointment of Douglas Liu, Senior Vice President of Global Operations at Qiagen, to its Board of Directors.

"Doug is an outstanding addition to our board," said Scott Carmer, BioHealth Innovation, Inc. Chairman of the Board and Executive Vice President of Commercial Operations at MedImmune. "His in-depth experience in strategic planning, operations and R&D in immunodiagnostics, molecular diagnostics, and other healthcare market sectors will prove invaluable as BHI drives biohealth commercialization opportunities in Central Maryland."

Mr. Liu currently serves as Senior Vice President of Global Operations for Qiagen, a German-based diagnostics company with a campus in Germantown, Maryland. He joined the company in 2005 after working at Bayer Healthcare as Head of Operations for Nucleic Acid Diagnostics in the U.S., and in Strategic Planning and Consulting at Bayer AG, Leverkusen. Mr. Liu has an M.B.A. from Boston University and a science degree from the University of Illinois. He also lived and worked in Germany for five years. Since returning to the U.S. in 2007, Mr. Liu has served on several local boards including the Governor's International Advisory Council & the board of MdBio/Tech Council of Maryland.

"I am honored to be part of an organization that has brought together key players in science, entrepreneurship and capital to change the dialogue about what we can be as a region," said Mr. Liu. "BHI's mission fits well with Qiagen's goal of advancing human health globally while contributing to the local economy and community."

Chairman Carmer expressed his appreciation for BHI's departing board member Dennis Fallen, who was with Rockville-based Fisher Biosciences and has accepted a position outside of the region. "Dennis served BHI well both as a work group member to help establish the organization and later as a board member," said Mr. Carmer. "We wish him the best in his new venture."

About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at

SOURCE BioHealth Innovation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy
2. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University
3. Senator Arlen Specter and Richard Gephardt Headline Policy Forum on U.S. Medical Innovation, Highlight Achieving Recovery Through Discovery
4. Kendle Realigns C-Suite Leadership to Drive Increased Innovation, Productivity and Organizational Efficiency
5. New Jerseys Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Omeros Appoints David A. Mann to its Board of Directors
8. RainDance Technologies Appoints Olex Vice President, System Development
9. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
10. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
11. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
Post Your Comments:
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):